<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1054">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475471</url>
  </required_header>
  <id_info>
    <org_study_id>RA1413</org_study_id>
    <nct_id>NCT04475471</nct_id>
  </id_info>
  <brief_title>WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey</brief_title>
  <acronym>WHF</acronym>
  <official_title>WHF COVID-19 and Cardiovascular Disease Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health Foundation of India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Chronic Disease Control, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Heart Federation, Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Public Health Foundation of India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A global study for a better understanding of the cardiovascular conditions that increase the
      risk of developing severe COVID-19, and a better characterization of cardiovascular
      complications in hospitalized patients with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 may be cardiotropic in a subset of patients. Both acute and pre-existing CVD impact
      outcomes unfavorably. It is possible that one common CVD treatment, medications that impact
      ACE-2 function, may impact outcomes either favorably or unfavorably.

      However, studies so far have, perforce, been conducted with important limitations (e.g. small
      numbers, limited geographical representation, lack of data standardization for risk factors
      and outcomes, limited measurement, lack of appropriate adjustment for important confounders,
      and missing data). Considering the high global prevalence of CVD and its risk factors (e.g.
      hypertension and diabetes) and the suggested link with COVID19 it is urgent to initiate more
      robust studies to clarify the many issues early reports have engendered. So that
      investigators will conduct a global study for a better understanding of the cardiovascular
      conditions that increase the risk of developing severe COVID-19, and a better
      characterization of cardiovascular complications in hospitalized patients with COVID-19.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the patients for major adverse cardiovascular events (MACE)</measure>
    <time_frame>Outcome will be assessed at discharge and 30-day follow-up visit from the hospital admission date.</time_frame>
    <description>MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure [including Left ventricular ejection fraction], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]</measure>
    <time_frame>at discharge and 30-day follow-up visits from the hospital admission date.</time_frame>
    <description>Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)</measure>
    <time_frame>at discharge and 30-day follow-up visits from the hospital admission date.</time_frame>
    <description>Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause deaths</measure>
    <time_frame>any time during the hospital admission and at 30-day follow-up.</time_frame>
    <description>Specific causes of death to be evaluated using CRF including sudden cardiac death, death due to Myocardial infarction, Death due to heart failure, death due to stroke</description>
  </primary_outcome>
  <enrollment type="Anticipated">5200</enrollment>
  <condition>COVID-19</condition>
  <condition>Cardiovascular Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited in any hospital where COVID19 patients are hospitalized.
        Investigators will invite all WHF members from 100+ countries to identify at least two
        recruiting centres in their respective countries. Each centre should recruit between 50 and
        200 consecutive patients. There is no limit in the number of sites to take part.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adults (as locally defined) with confirmed COVID-19 infection who are hospitalized
             are eligible.

        Exclusion Criteria:

          -  Patients for whom investigators are unable to obtain informed consent will be
             excluded.

          -  Patients who are unlikely to stay in the recruiting centre for 30 days (i.e. likely to
             be transferred)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KAREN SILWA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo PEREL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KAVITA SINGH, PhD</last_name>
    <phone>9899691150</phone>
    <phone_ext>91</phone_ext>
    <email>kavita@ccdcindia.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DORAIRAJ PRABHAKARAN, MD, DM</last_name>
    <phone>124-4781400</phone>
    <phone_ext>91</phone_ext>
    <email>dprabhakaran@phfi.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clinicas of the University</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo P. de la Hoz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas of the University</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M. Aladio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas of the University</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maia Matsudo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas of the University</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Swieszkowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas of the University</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejo P. de la Hoz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio GÃ¼emes Hospital</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ezequiel J. Zaidel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Republic of Srpska</name>
      <address>
        <city>Srpska</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Stanetiic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Komfo Anokye Teaching Hospital</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lambert T. Appiah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumasi South Regional Hospital</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lambert T. Appiah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayanand medical college hospital</name>
      <address>
        <city>Ludhiyana</city>
        <state>Punjab</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bishav Mohan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amin Hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizal Sarrafzadegan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amin Hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ladan Sadeghian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Khorshid Hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sayed M. Hashemi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fedail Hospital</name>
      <address>
        <city>Khartoum</city>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Suliman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bosnia and Herzegovina</country>
    <country>Ghana</country>
    <country>India</country>
    <country>Iran, Islamic Republic of</country>
    <country>Sudan</country>
  </location_countries>
  <link>
    <url>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200316-sitrep-56-covid-19.%20pdf?sfvrsn=9fda7db2_6</url>
    <description>WHO. Coronavirus disease 2019 (COVID-19) situation report-56</description>
  </link>
  <reference>
    <citation>Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016 Jun 1;1(3):274-81. doi: 10.1001/jamacardio.2016.0433.</citation>
    <PMID>27438105</PMID>
  </reference>
  <reference>
    <citation>Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW 3rd. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007 May;28(10):1205-10. Epub 2007 Apr 17.</citation>
    <PMID>17440221</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </reference>
  <reference>
    <citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.</citation>
    <PMID>32139904</PMID>
  </reference>
  <reference>
    <citation>Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.</citation>
    <PMID>32173574</PMID>
  </reference>
  <reference>
    <citation>Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286.</citation>
    <PMID>32219363</PMID>
  </reference>
  <reference>
    <citation>Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi: 10.1056/NEJMoa1702090.</citation>
    <PMID>29365305</PMID>
  </reference>
  <reference>
    <citation>Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x. Epub 2009 May 6.</citation>
    <PMID>19453650</PMID>
  </reference>
  <reference>
    <citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.</citation>
    <PMID>32211816</PMID>
  </reference>
  <reference>
    <citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.</citation>
    <PMID>32219356</PMID>
  </reference>
  <reference>
    <citation>Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391. doi: 10.1016/j.pcad.2020.03.001. Epub 2020 Mar 10. Review.</citation>
    <PMID>32169400</PMID>
  </reference>
  <reference>
    <citation>Yang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. JAMA Cardiol. 2020 Jul 1;5(7):743-744. doi: 10.1001/jamacardio.2020.0934.</citation>
    <PMID>32211809</PMID>
  </reference>
  <reference>
    <citation>Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):819-824. doi: 10.1001/jamacardio.2020.1096.</citation>
    <PMID>32219357</PMID>
  </reference>
  <reference>
    <citation>Ribeiro AH, Ribeiro MH, PaixÃ£o GMM, Oliveira DM, Gomes PR, Canazart JA, Ferreira MPS, Andersson CR, Macfarlane PW, Meira W Jr, SchÃ¶n TB, Ribeiro ALP. Automatic diagnosis of the 12-lead ECG using a deep neural network. Nat Commun. 2020 Apr 9;11(1):1760. doi: 10.1038/s41467-020-15432-4. Erratum in: Nat Commun. 2020 May 1;11(1):2227.</citation>
    <PMID>32273514</PMID>
  </reference>
  <reference>
    <citation>Alkmim MB, Silva CBG, Figueira RM, Santos DVV, Ribeiro LB, da PaixÃ£o MC, Marcolino MS, Paiva JC, Ribeiro AL. Brazilian National Service of Telediagnosis in Electrocardiography. Stud Health Technol Inform. 2019 Aug 21;264:1635-1636. doi: 10.3233/SHTI190571.</citation>
    <PMID>31438267</PMID>
  </reference>
  <results_reference>
    <citation>Thienemann F, Pinto F, Grobbee DE, Boehm M, Bazargani N, Ge J, Sliwa K. World Heart Federation Briefing on Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries. Glob Heart. 2020 Apr 9;15(1):31. doi: 10.5334/gh.778.</citation>
    <PMID>32489804</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </results_reference>
  <results_reference>
    <citation>Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11. Review.</citation>
    <PMID>32161990</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </results_reference>
  <results_reference>
    <citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. Erratum in: Lancet Respir Med. 2020 Jun;8(6):e54.</citation>
    <PMID>32171062</PMID>
  </results_reference>
  <results_reference>
    <citation>Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004 Dec 16;351(25):2611-8.</citation>
    <PMID>15602021</PMID>
  </results_reference>
  <results_reference>
    <citation>Alsahafi AJ, Cheng AC. The epidemiology of Middle East respiratory syndrome coronavirus in the Kingdom of Saudi Arabia, 2012-2015. Int J Infect Dis. 2016 Apr;45:1-4. doi: 10.1016/j.ijid.2016.02.004. Epub 2016 Feb 10.</citation>
    <PMID>26875601</PMID>
  </results_reference>
  <results_reference>
    <citation>Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016 Jan-Feb;36(1):78-80. doi: 10.5144/0256-4947.2016.78.</citation>
    <PMID>26922692</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Public Health Foundation of India</investigator_affiliation>
    <investigator_full_name>Dorairaj Prabhakaran</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Below is the detail of the data to be collected from each patient enrolled in the study:
Patient demographics: age, sex, ethnicity, weight/height and education level
Clinical history: smoking status, hypertension, diabetes, obesity, heart failure, rheumatic heart disease, chagas, history of Coronary artery disease/ Percutaneous Coronary Interventions/ Coronary artery bypass graft surgery
Usual medication (before hospitalization)
Clinical characteristics at presentation: confirmed diagnosis of COVID-19, heart rate, blood pressure
Tests: ECG, ECHO, troponin, NT-proBNP and other biochemical markers
Medication received during hospitalization: cardiovascular and non-cardiovascular medications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Two years after study completion and publication of main study results i.e., Dec 2023</ipd_time_frame>
    <ipd_access_criteria>Two years after study completion and publication of main study results i.e., Dec 2023, and upon request from external researchers being sent to the study PIs and study steering committee for review and approval</ipd_access_criteria>
    <ipd_url>https://www.world-heart-federation.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

